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Multiple sclerosis (MS) is a complex debilitating disease of the central nervous system
(CNS) perceived to result from the autoimmune effect ofT cells in damaging myelin sheath.
However, the exact pathogenesis of the disease remains elusive. Initial studies describ-
ing the possibility of defective pyruvate metabolism in MS were performed in 1950s. The
group observed elevated blood pyruvate level in both fasting and postprandial times in MS
patients with relapse. Similarly, other investigators also reported increased fasting pyruvate
level in this disease.These reports hint to a possible abnormality of pyruvate metabolism in
MS patients. In addition, increase in levels of Krebs cycle acids like alpha-ketoglutarate in
fasting and citrate after glucose intake in MS patients further strengthened the connection
of disturbed pyruvate metabolism with MS progression.These studies led the investigators
to explore the role of disturbed glucose metabolism in pathophysiological brain function.
Under normal circumstances, complex molecules are metabolized into simpler molecules
through their respective pathways. Differential expression of genes encoding enzymes of
the glucose metabolic pathway in CNS may result in neurological deficits. In this review arti-
cle, we discuss the studies related to disturbed carbohydrate metabolism in MS and other
neurodegenerative diseases. These observations open new perspectives for the under-
standing of metabolic dynamics in MS yet many puzzling aspects and critical questions
need to be addressed. Much more research is required to fully unravel the disease mecha-
nism, and a proper understanding of the disease could eventually lead to new treatments.
Keywords: brain glucose metabolism, cell-specific mechanisms, mitochondrial defects, multiple sclerosis,
neurodegenerative diseases
INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disease of proba-
bly immune origin affecting more than two million people world-
wide. Demyelinated plaque, inflammatory infiltrates, accumula-
tion of antibodies, and complement proteins are the pathological
hallmarks of MS (1). It is believed that immune cells particularly T
cells penetrate the brain and mistakenly recognize myelin tissue as
foreign and damage it. The inflammatory cells including microglia,
macrophages; antibodies, cytokines, complement system, and oth-
ers enhance the damaging effect. The process of demyelination is
associated with axonal degeneration that underlies neurological
deficits in MS (2). The lesions formed as a consequence of neu-
roaxonal injury are found in both white and gray matter of the
central nervous system (CNS) (3). Although research underscores
the role of immunological, genetic, and environmental pathologic
influences, the exact mechanisms underlying MS pathology are yet
uncertain.
Abbreviations: CNS, central nervous system; ETC, electron transport chain; FAD,
flavin adenine dinucleotide; MS, multiple sclerosis; NAD+, nicotinamide ade-
nine dinucleotide; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary
progressive multiple sclerosis; TCA cycle, tricarboxylic acid cycle.
The disease course often begins with clinically isolated syn-
drome involving optic nerve, brain stem or spinal cord. The
70–80% of these patients experience relapsing-remitting events,
which at later stage are transformed into a secondary progressive
stage that causes irreversible neurologic worsening. This suggests
that the pathophysiology of progression is not solely inflammatory
in nature (4). To prevent disease progression investigators have
explored a possible role of energy metabolism in the CNS. Meta-
bolic disturbances have been implicated in neurodegenerative
disorders including Alzheimer’s, Huntington’s, and Parkinson’s
diseases. In demyelinating diseases particularly MS, investiga-
tions on the contribution of disturbed glucose metabolism in MS
pathology are limited. However, the existing literature hints to a
connection between disturbed glucose metabolism and MS patho-
genesis. In this context, this article will first focus on some basic
aspects of brain’s energy balance, its regulation at cellular level,
and its role in normal and diseased conditions with a special focus
on MS. Before we discuss the cell-specific mechanisms underly-
ing brain energy metabolism, it seems pertinent to briefly review
the metabolic pathways, which include glycolysis, the tricarboxylic
acid (TCA) cycle, and the pentose phosphate pathway (PPP). These
metabolic pathways are similar in brain and other tissues.
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GLYCOLYSIS
Glycolysis (Embden–Meyerhof pathway) is the metabolism of
glucose to pyruvate. Four ATP molecules are produced in the
processing of glucose to pyruvate, where two ATP molecules are
consumed in the pathway resulting in a net production of two
ATP molecules per glucose molecule. In the absence of oxygen
(anaerobic conditions), pyruvate is converted into lactate, allowing
the regeneration of nicotinamide adenine dinucleotide (NAD+),
which is necessary to maintain a continued glycolytic flux. Without
the regeneration of NAD+ the pathway could not have continued
beyond glyceraldehyde 3-phosphate.
TRICARBOXYLIC ACID CYCLE
Under aerobic conditions, pyruvate undergoes oxidative decar-
boxylation to yield acetyl-CoA in a reaction catalyzed by pyruvate
dehydrogenase. Acetyl-CoA in the presence of citrate synthase con-
denses with oxaloacetate and forms citrate. This is the first step of
the TCA cycle in which three molecules of NADH are formed from
NAD+ and one molecule of FADH2 is formed from flavin ade-
nine dinucleotide (FAD) through four oxidation–reduction steps.
The reducing equivalents NADH and FADH2 transfer their elec-
trons to molecular oxygen via mitochondrial electron transport
chain (ETC). There are five enzyme complexes, denoted as I–V
that forms the ETC in mitochondria. Electron transfer from com-
plexes I and II to complex III and from complex III to complex
IV is accomplished by co-enzymes ubiquinone and cytochrome
c. During this process, protons are transported across the inner
mitochondrial membrane to the intermembrane space to gener-
ate an electrochemical gradient. The enzyme ATP synthase utilizes
this energy and produces ATP.
PENTOSE PHOSPHATE PATHWAY
Overall, glucose is completely oxidized to carbon dioxide and water
via three synchronized pathways namely glycolysis, the TCA cycle,
and the ETC, and finally produces energy in the form of ATP. How-
ever, there are conditions when extra metabolic energy is required
in the form of reducing power in addition to ATP. These are the
situations when precursors are in a more oxidized state than the
products. In PPP, glucose 6-phosphate is converted into ribulose
5-phosphate utilizing two molecules of NAD+. Thus, when ample
amount of energy is required, the level of NADPH falls down and
the pathway is activated to generate more reducing equivalents.
GLUCOSE SERVING AS THE MAIN FUEL IN BRAIN
The human brain represents only 2% of the body weight, yet 25%
of total body glucose is utilized by it. Energy requirement is high-
est in neurons of adult brain (5). Therefore, a continuous supply
of glucose is needed from bloodstream into the brain. With a few
exceptions, glucose is the main source of energy in mammalian
brain (6). Nevertheless, there are certain circumstances when brain
uses ketone bodies as energy source including starvation, during
strenuous exercise and development (7). Metabolism of glucose
yields energy in the form of ATP that is used for neuronal and
non-neuronal cell survival and generation of neurotransmitters.
Therefore, tight regulation of glucose metabolism is necessary for
normal brain physiology and perturbation in any step of its regu-
lation pathway may form the pathophysiological nexus for many
brain disorders.
CELL-SPECIFIC MECHANISMS UNDERPINNING BRAIN
ENERGY METABOLISM
GLIA AND VASCULAR ENDOTHELIAL CELLS – ROLE IN BRAIN ENERGY
METABOLISM
Neurons are usually regarded the most important cells of the CNS
taking part in energy metabolism. However, other cells like glial
and vascular endothelial cells also play a critical role in the distrib-
ution of energy substrates to neurons. Glial cells constitute nearly
half of the brain volume. Out of many different cell types in the
brain, neurons represent only a small proportion for glucose uti-
lization. It has been seen that the presence of specialized end-feet
processes makes astrocytes the first cellular barrier that glucose
entering the brain parenchyma come across and makes them a
probable site of glucose uptake and energy substrate distribution.
Besides possessing end-feet processes, astrocytes contain processes
that ensheathe synaptic contacts. The receptors and uptake sites
present on astrocytes allow neurotransmitters to communicate
with them. These structural and functional characteristics exhib-
ited by astrocytes makes them perfectly suitable to couple local
changes in neuronal activity with coordinated adaptations in
energy metabolism.
GLUCOSE METABOLISM IS TIGHTLY REGULATED IN ALL CELL TYPES OF
THE BRAIN – NEURONAL AND NON-NEURONAL
Due to enormous degree of cellular heterogeneity in brain, it is
quite cumbersome to understand the relative role of each cell
type in energy substrate flux. However, usage of primary cultures
in vitro enriched in neurons, astrocytes or vascular endothelial
cells have proved very beneficial in localizing the cellular sites
for glucose uptake and its consequent metabolic fate particu-
larly as regards glycolysis and oxidative phosphorylation. As it is
well understood that in situ cellular preparation does not exhibit
all the properties as observed in whole brain tissues many other
aspects of brain energy metabolism can be studied using cultures
in vitro.
Under basal conditions, glucose uptake and its utilization occur
in all cell types of the brain with a high specificity. This is due to
the presence of unique glucose transporters (GLUTs) on different
cell types. Due to low lipid solubility and lack of specific trans-
port carriers in the luminal membrane of the capillary endothelial
cell entry of neuroactive compounds such as glutamate, aspartate,
and glycine into the blood–brain barrier is limited. Glucose being
an obligatory fuel enters through facilitated transport mechanism
mediated by specific transporters. Six genes and one pseudogene
encoding glucose transporter proteins have been identified so far.
These are designated as GLUT1 to GLUT7 (8). In brain, GLUT1,
3, and 5 are preponderantly expressed in cell-specific manner (9).
Based on the degree of glycosylation, GLUT1 is expressed in two
forms in the brain with molecular weight 55 and 45 kDa (10,
11). The 55 kDa form of GLUT1 is expressed in choroid plexus,
ependymal cells, and vascular endothelial cells. The other form
with 45 kDa molecular mass is localized on astrocytes (12). Neu-
rons possess GLUT3 transporter on their membrane (13) whereas
microglial cells, the resident macrophages of the brain, are found
to have GLUT5 form of the transporter (9). So, it is apparent that
glucose enters the brain via 55 kDa GLUT1 receptor present on
endothelial cells. The uptake by astrocytes is mediated by 45 kDa
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form of GLUT1 while GLUT3 receptors mediate this process
in neurons. Ultimately, microglial cells uptake glucose from the
surrounding medium through GLUT5 receptor.
GLUCOSE METABOLISM AND MULTIPLE SCLEROSIS
Studies show that there is a possible role of impaired energy
metabolism in the CNS of MS patients (Figure 1). Initial stud-
ies describing the possibility of defective pyruvate metabolism
in MS were performed by Jones et al. (14). The group observed
elevated blood pyruvate level in both fasting and postprandial
times in MS patients with relapse. Similarly, other investigators
also reported increased fasting pyruvate level in this disease (15).
However, there were conflicting reports demonstrating normal
fasting lactate level, or increase in only a small number of patients
(16–18). On the other hand, Jeanes and Cumings (16) found an
abnormal rise in the blood pyruvate level after glucose intake.
These reports hint to a possible abnormality of pyruvate metabo-
lism in MS patients. In addition, increase in levels of Krebs cycle
acids like alpha-ketoglutarate in fasting and citrate after glucose
intake in MS patients further strengthened the connection of dis-
turbed pyruvate metabolism with MS progression (18). McArdle
et al. (19) found elevated levels of pyruvate and α-ketoglutarate
Glucose
Glucose-6-Phosphate                         
Fructose-6-Phosphate
Fructose-1,6-Bisphosphate
GLAP   DHAP
1,3-Bisphosphoglycerate
3-Phosphoglycerate
2-Phosphoglycerate
Phosphoenolpyruvate
Pyruvate
Lactate
Glucose
GLUTs
MCTs
         Tpi
Mitochondria
Cytosol
ATP synthase
Oxidative 
PhosphorylationTCA 
cycle
30-34 ATP
CO2 + H2O
Defective
Defective
Defective
                        Ribulose 5-Phosphate
6-PGL  
Pentose Phosphate
Pathway
Defective
Glycolysis
Demyelinated plaques 
in brain and spinal cord
Glycogen
O2
I        II     III      IV     V
Hk
Gpi
Pfk
Aldolase
Gapdh
Pgk
Pgam
Eno
Pk
Ldh
Pdh
FIGURE 1 | Schematic representation of glucose metabolism in MS
brain. Glucose enters cells through GLUTs and is phosphorylated by
hexokinase to produce glucose 6-phosphate. Glucose 6-phosphate can be
processed into three main coordinated metabolic pathways. First, it can be
metabolized through glycolysis giving rise to two molecules of pyruvate
and producing ATP and NADH. Pyruvate can then enter mitochondria,
where it is metabolized through the TCA cycle and oxidative
phosphorylation, producing ATP and CO2. Alternatively, pyruvate can be
reduced to lactate by Ldh. This lactate can be released into the
extracellular space through monocarboxylate transporters (MCTs). The
complete oxidation of glucose produces 30–34 ATP molecules in the
mitochondria. Alternatively, glucose 6-phosphate can be processed
through the PPP leading to the production of reducing equivalent in the
form of NADPH. Note that the PPP and glycolysis are linked at the level of
glyceraldehyde-3-phosphate (GLAP) and fructose 6-phosphate. Finally,
glucose 6-phosphate can be converted to glycogen through the process of
glycogenesis in astrocytes. Hk, hexokinase; Gpi, glucose-6-phosphate
isomerase; Pfk, phosphofructokinase-1; DHAP, dihydroxyacetone
phosphate; Tpi, triose phosphate isomerase; GAPDH,
glucose-6-phosphate dehydrogenase; Pgk, phosphoglycerate kinase;
Pgam, phosphoglycerate mutase; Eno, enolase; Pk, pyruvate kinase; Ldh,
lactate dehydrogenase; 6-PGL, 6-phosphoglucono-d-lactone.
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in MS. Increased activity of metabolic enzymes including enolase,
pyruvate kinase, lactate dehydrogenase (Ldh), and aldolase in the
CSF of patients with disseminated sclerosis make them a sensitive
indicator of active demyelination (20).
B cells and antibodies reactive with triose phosphate isomerase
(TPI) and GAPDH are produced intrathecally in CSF and lesions
of MS (21). Both TPI and GAPDH are essential metabolic enzymes
involved in ATP production. Another investigation by the same
group showed that these antibodies bind with TPI and GAPDH
and inhibit the glycolytic activity of GAPDH but not TPI in MS
patients (22). This inhibitory effect of antibodies on GAPDH was
not visualized when anti-GAPDH IgG was exhausted from the CSF
demonstrating the role of anti-GAPDH antibodies in impeding
the GAPDH enzyme activity in brain leading to neuronal apopto-
sis and cytotoxicity. In systemic lupus,an autoimmune rheumatoid
disorder, autoantibodies were found reactive to GAPDH (23).
Accumulating evidence indicates that inhibition of GAPDH activ-
ity in glycolytic pathway is associated with neuronal apoptosis. It
has been purported that GAPDH enzyme activity suppresses when
it reacts with other proteins in the CNS (24). Single chain variable
fragment antibodies (scFv-abs) obtained from clonally expanded
B cells binds specifically with GAPDH and TPI in active MS lesions
(25). In addition, interaction of GAPDH with ß-amyloid protein
and Huntingtin protein well demonstrates the role of GAPDH in
neurodegenerative disorders (26).
A recent study demonstrated that a ligand-activated transcrip-
tion factor known as peroxisome proliferator-activated receptor
gamma (PPARγ) playing a pivotal role in regulation of glu-
cose and lipid metabolism is markedly increased in CSF of MS
patients (27). Furthermore, elevated expression of PPARγ has
been reported within the spinal cord of EAE mice (28) and in
an in vitro model of antigen induced demyelination (29). These
findings may contribute to our understanding about the role of
PPARγ in the pathogenesis of MS. William et al. studied the role
of CNS energy metabolism in MS disease progression. The group
measured the levels of lactate, sorbitol, and fructose, all metabo-
lites of extra-mitochondrial glucose metabolism, in the CSF of
relapsing remitting and secondary progressive MS patients (30).
Sorbitol and fructose are the metabolites of polyol pathway that
run parallel to glycolysis and lactate is the metabolite of anaer-
obic pathway. The finding demonstrated elevated levels of all
three metabolites in the CSF of SPMS patients and to a lesser
extent to RRMS patients (Figure S1 in Supplementary Mater-
ial). These alterations in energy metabolism may contribute to
mitochondrial dysfunction and neuroaxonal degeneration under-
lying MS progression. Taken together, the finding supports a
link between increased activity of extra-mitochondrial pathways
of glucose metabolism and MS disease progression. Other stud-
ies found that the activity of enolase, pyruvate kinase, Ldh, and
aldolase, all metabolic enzymes was increased in disseminated
sclerosis (20).
A recent investigation demonstrated differences in the gene
expression levels of various NADPH subunits between initial MS
lesions and control white matter brain. The group performed
whole genome profiling of MS brain tissue and observed signif-
icant up regulation of nicotinamide dinucleotide phosphate oxi-
dase I and nicotinamide dinucleotide phosphate oxidase organizer
I in active MS lesions (31). NADPH oxidase is a multi-subunit
enzyme complex that is activated under pathological condi-
tions in microglia and catalyzes the production of superoxide
from O2. Other studies have identified defects in mitochon-
drial electron transport gene expression and function in post-
mortem MS cortex (32, 33). These studies have found tran-
scriptional changes in important mitochondrial genes; however,
translational or post-translational changes in several other pro-
teins may also influence mitochondrial function and energy
production.
MITOCHONDRIAL DEFECTS IN MS
Mitochondrial dysfunction is implicated in various pathological
conditions like diabetes, anxiety disorders, neurodegenerative dis-
eases such as Alzheimer’s, Huntington’s, and Parkinson’s disease,
and cancer and fatigue (see for instance Table 1). It is only recently
that mitochondrial aberrations have been studied in MS. Unlike
nuclear DNA, mitochondrial DNA (mtDNA) is not surrounded
by histones, proteins that shield nuclear DNA from free radicals.
Therefore it is quite prone to damage. The number of mitochon-
dria in a cell is determined by its energy requirement. For instance,
there may be up to 200–2000 mitochondria present in a single
somatic cell whereas the number is fixed to 16 in spermatozoa germ
cells and 100,000 in oocytes. Metabolically active cells like skele-
tal muscle, cardiac muscle, and brain contain largest number of
mitochondria. It has been seen that the number of mitochondria
and their activity is increased in MS plaques (34). In demyeli-
nating diseases particularly MS, it is likely that cells need ample
energy to survive. Hence, metabolic activity of biomolecules in
mitochondria increases with concomitant impairment of Krebs
cycle and/or neuronal oxidative phosphorylation within the CNS.
Another study revealed a reduction in ATP synthase expression in
MS lesions (35). Mitochondrial proteins are expressed in greater
amounts in both active and inactive lesions. Activity of complex
IV found on mitochondrial membrane is increased dramatically
in MS lesions (30). Lu et al. (36) revealed defects in complex I
component of ETC in white matter lesions. Furthermore, reduced
functional activity of complex I and complex III and a decrease in
gene expression of complex I, complex III, complex IV, and ATP
synthase has been observed in non-lesional motor cortex (33).
A recent finding demonstrated changes in mitochondrial com-
plex enzyme activities and cytochrome c expression in platelets of
MS patients. Krebs cycle enzyme aconitase activity was higher in
patients without fatigue and all respiratory complex enzyme activ-
ities (complex I, II, III, IV, and V) were higher in MS patients com-
pared to controls. Complex II activity increased significantly in MS
group between patients with and without fatigue (42). Interest-
ingly, a significant reduction in the gene expression of cytochrome
c oxidase 5B subunit (COX5B) was observed in MS patients (46).
This data suggest that there is a down regulation of genes associated
with mitochondrial ETC. Analysis of a number of respiratory chain
proteins reveals functionally important defects of mitochondrial
proteins [cytochrome c oxidase (COX) and its catalytic compo-
nent, COX-1] in complex III in MS (47). Different expressions of
mitochondrial proteins namely cytochrome c oxidase subunit 5b
(COX5b), hemoglobin ß, creatine kinase, and myelin basic protein
(MBP) were found in the brain of MS (48). Taken together, these
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Table 1 | Comparison of disturbed glucose metabolism in MS and other neurodegenerative disorders.
Glucose metabolism Multiple sclerosis Other neurodegenerative disorders
Glycolysis Elevated blood pyruvate level was observed in both fasting and
postprandial times in MS patients with relapse (14)
Impaired GAPDH function was observed in subcellular
fractions of fibroblasts from Alzheimer and Huntington
patients (37)
GAPDH was found to be overexpressed in the neocortex
and caudate putamen neurons in a transgenic model of
Huntington’s disease (38)
The activity of GAPDH, hexokinase and pyruvate
kinase was increased in Alzheimer’s disease (AD) (39)
Pyruvate levels were found to be increased in MS (19)
The activity of metabolic enzymes including enolase and pyruvate
kinase was found to be increased in the CSF of MS patients (20)
Antibodies reactive with triose phosphate isomerase (TPI) and
GAPDH, bind with them and inhibit the glycolytic activity of
GAPDH in MS patients (22)
The levels of enolase, pyruvate kinase, Ldh, and aldolase, all
metabolic enzymes were increased in MS (20)
TCA cycle Krebs cycle proteins like α-ketoglutarate levels in fasting and
citrate levels after glucose intake were found to be increased in
MS patients (18)
Mitochondrial aconitase, succinyl-CoA synthetase β,
fumarase and malate dehydrogenase showed
decreased gene expression in hippocampal samples from
autopsy AD brains in two independent studies (40, 41)
Mitochondrial oxoglutarate dehydrogenase, showed
increased and decreased gene expression in moderate
and severe AD patients (40)
α-Ketoglutarate levels were found to be increased in MS (19)
Krebs cycle enzyme aconitase activity was found to be higher in
MS patients without fatigue (42)
Oxidative
phosphorylation
A reduction in the expression of ATP synthase gene was
observed in MS lesions (35)
Decreased mRNA expression levels of ETC proteins,
specifically FAD synthetase, riboflavin kinase (RFK),
cytochrome C1 (CYC1), and succinate dehydrogenase
complex subunit B were reported in amyotrophic lateral
sclerosis (43)
Decreased mRNA levels of the mitochondrial-encoded
cytochrome oxidase (COX) subunits I, II, and III were
observed in brains of AD patients (41, 44, 45)
Reduced expression of nuclear encoded subunits of
mitochondrial enzymes of oxidative phosphorylation
including subunit IV of COX and the beta-subunit of
the F0F1-ATP synthase was also observed in vulnerable
areas of AD brains (41, 44)
Activity of mitochondrial ETC complex IV was increased
dramatically in MS lesions (30)
Defects in complex I component of mitochondrial ETC were
observed in white matter lesions (36)
Furthermore, reduced functional activity of complex I and
complex III and a decrease in gene expression of complex I,
complex III, complex IV, and ATP synthase has been observed
in non-lesional motor cortex (33). In contrast, enzyme activities of
complex I, II, III, IV, and V were found to be higher in MS patients
compared to controls. Complex II activity increased significantly
in MS group between patients with and without fatigue (42)
A significant reduction in the gene expression of cytochrome c
oxidase 5B subunit (COX5B) was observed in MS patients (46)
Analysis of a number of respiratory chain proteins reveals
functionally important defects of mitochondrial proteins
[cytochrome c oxidase (COX) and its catalytic component,
COX-1] in complex III in MS (47)
Different expression of mitochondrial proteins namely
cytochrome c oxidase subunit 5b (COX5b), hemoglobin β,
creatine kinase, and myelin basic protein (MBP) was found in
the brain of MS (48)
studies show mitochondrial abnormalities that may cause func-
tional disturbance in the surviving demyelinated axons in MS and
may result in neurological dysfunction.
GLUCOSE METABOLISM AND NEURODEGENERATIVE
DISORDERS
A body of evidence indicates a link between disturbed meta-
bolic function and the progression of neurodegenerative diseases
like AD, Huntington’s disease and Parkinson’s disease. A report
documented that GAPDH glycolytic function is impaired in sub-
cellular fractions of fibroblasts from Alzheimer and Huntington
patients whereas the gene expression remained unchanged (37).
This might have occurred due to post-translational modification
of the GAPDH protein. In a transgenic model of Huntington’s
disease, GAPDH is seen to be overexpressed in specific neuronal
populations of several brain regions, such as the neocortex and
caudate putamen neurons. This study also revealed translocation
of GAPDH into the nucleus and the subsequent cell loss in the
neocortex and caudate putamen region of the brain (38). Sim-
ilar finding was observed by Bae et al. (49), who demonstrated
that GAPDH facilitates nuclear translocation of mutant Hunt-
ingtin protein (mHtt) and causes neurotoxicity. In Aβ (amyloid
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beta) resistant cells of Alzheimer’s brain, glycolytic pathway was
upregulated and hexose monophosphate shunt (HMS) was acti-
vated. The activity of GAPDH, hexokinase, and pyruvate kinase
was increased in both glycolysis and HMS (39). In amyotrophic lat-
eral sclerosis (ALS), abnormalities in ETC have been reported. The
study found decreased mRNA expression levels of ETC proteins,
specifically FAD synthetase, riboflavin kinase (RFK), cytochrome
C1 (CYC1), and succinate dehydrogenase complex subunit B
(SDHB) (43).
CONCLUSION
Despite extensive research being carried out for a decade the
underlying cause of MS still remains elusive. Perturbed glucose
metabolism is implicated in neurodegenerative disorders like
Alzheimer’s, Parkinson’s, and Huntington’s. However, little is
known about its role in MS pathology. The observations reviewed
in this article, especially those referred with mitochondrial aber-
rations and impaired glucose metabolism in MS, pointed to a
relationship between glucose metabolism and MS disease patho-
genesis. Although traditionally considered as an autoimmune,
inflammatory, and demyelinating disease of the CNS, the scenario
of MS pathogenesis associated with metabolic abnormalities is
speculated.
These observations open new perspectives for the understand-
ing of metabolic dynamics in MS yet many puzzling aspects and
critical questions need to be addressed. For instance, how does
defect in metabolic pathway contributes to demyelination? Does
metabolic pathway alter in other cell types in MS? The changes in
a cell type, may affect directly, through some unknown factor, or
indirectly, through global changes in metabolic intermediates lev-
els in CSF, to other cell types? Is disturbance in metabolic pathway
a mere cause or a consequence of MS? Could those genes be used
as a pharmacological target to alleviate MS pathology? Much more
research is required to fully unravel the disease mechanism, and a
proper understanding of the disease could eventually lead to new
treatments.
ACKNOWLEDGMENTS
This work was supported by a grant from the Health Research Fund
of the Institute of Health Carlos III. Sub aid of Strategic Action for
Health in the framework the National R+D+I 2009–2012. Expte:
PS09/00976.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at http://www.frontiersin.org/Journal/10.3389/fneur.2014.00250/
abstract
REFERENCES
1. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in
acute multiple sclerosis lesions. Brain (1997) 120(3):393–9. doi:10.1093/brain/
120.3
2. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: con-
sequences for understanding the progressive phase of the disease. J Neurol Sci
(2003) 206(2):165–71. doi:10.1016/S0022-510X(02)00069-2
3. Bö L, Geurts JJG, Mörk SJ, van der Valk P. Gray matter pathology in multiple
sclerosis. Acta Neurol Scand (2006) 113:48–50. doi:10.1111/j.1600-0404
4. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of
disability in multiple sclerosis. N Engl J Med (2000) 343:1430–8. doi:10.1056/
NEJM200011163432001
5. Howarth C, Gleeson P, Attwell D. Updated energy budgets for neural com-
putation in the neocortex and cerebellum. J Cereb Blood Flow Metab (2012)
32:1222–32. doi:10.1038/jcbfm.2012.35
6. Kety SS. The general metabolism of the brain in vivo. In: Richter D, editor.
Metabolism of the nervous system. London: Pergamon (1957). p. 221–37.
7. Nehlig A. Brain uptake and metabolism of ketone bodies in animal models.
Prostaglandins Leukot Essent Fatty Acids (2004) 70:265–75. doi:10.1016/j.plefa.
2003.07.006
8. Gould GW, Holman GD. The glucose transporter family: structure, function
and tissue-specific expression. Neurosci Lett (1993) 97:209–14.
9. Maher F,Vannucci SJ, Simpson IA. Glucose transporter proteins in brain. FASEB
J (1994) 8:1003–11.
10. Birnbaum MJ, Haspel HC, Rosen OM. Cloning and characterization of a cDNA
encoding the rat brain glucose transporter protein. Proc Natl Acad Sci U S A
(1986) 83:5784–8. doi:10.1073/pnas.83.16.5784
11. Kasaniki MA, Cairns MT, Davies A, Gardiner RM, Baldwin SA. Identification
and characterization of the glucose transport protein of the bovine blood–brain
barrier. Biochem J (1987) 247:101–8.
12. Morgello S, Uson RR, Schwartz EJ, Haber RS. The human blood-brain barrier
glucose transporter (GLUT1) is a glucose transporter of gray matter astrocytes.
Glia (1995) 14:43–54. doi:10.1002/glia.440140107
13. Bondy CA, Lee WH, Zhou J. Ontogeny and cellular distribution of brain glucose
transporter gene expression. Mol Cell Neurosci (1992) 3:305–14. doi:10.1016/
1044-7431(92)90027-Y
14. Jones HH, Jones HH Jr., Bunch LD. Biochemical studies in multiple sclerosis.
Ann Intern Med (1950) 33(4):831–40.
15. Ervenich P. Atrzl. Prax., Lpz. (1952) 4:2.
16. Jeanes AL, Cumings JN. Some laboratory investigations in multiple sclerosis.
Confin. Neurol. (Basel) (1958) 18(6):397–404.
17. Bauer H. Biochem Z (1956) 327:491.
18. Henneman DH, Altschule MD, Goncz RM, Alexander L. Carbohydrate metab-
olism in brain disease. I. Glucose metabolism in multiple sclerosis. A.M.A. Arch.
Neurol. Psychiat. (1954) 72(6):688–95.
19. McArdle B, Mackenzie ICK, Webster GR. Studies on intermediate carbohydrate
metabolism in multiple sclerosis. J Neurol Neurosurg Psychiat (1960) 23:127.
doi:10.1136/jnnp.23.2.127
20. Royds JA, Timperley WR, Taylor CB. Levels of enolase and other enzymes in the
cerebrospinal fluid as indices of pathological change. J Neurol Neurosurg Psychiat
(1981) 44:1129–35. doi:10.1136/jnnp.44.12.1129
21. Kölln J, Ren HM, Da RR, Zhang Y, Spillner E, Olek M, et al. Triosephosphate
isomerase- and glyceraldehyde-3-phosphate dehydrogenase-reactive autoanti-
bodies in the cerebrospinal fluid of patients with multiple sclerosis. J Immunol
(2006) 177:5652–8. doi:10.4049/jimmunol.177.8.5652
22. Kölln J, Zhang Y, Thai G, Demetriou M, Hermanowicz N, Duquette P, et al.
Inhibition of glyceraldehyde-3-phosphate dehydrogenase activity by antibodies
present in the cerebrospinal fluid of patients with multiple sclerosis. J Immunol
(2010) 185:1968–75. doi:10.4049/jimmunol.0904083
23. Takasaki Y, Kaneda K, Matsushita M, Yamada H, Nawata M, Matsudaira R,
et al. Glyceraldehyde 3-phosphate dehydrogenase is a novel autoantigen leading
autoimmune responses to proliferating cell nuclear antigen multiprotein com-
plexes in lupus patients. Int Immunol (2004) 16:1295–304. doi:10.1093/intimm/
dxh131
24. Burke D. Demyelination in optic neuritis and its effects on the visual evoked
potential. Aust J Ophthalmol (1983) 11:341–5. doi:10.1111/j.1442-9071
25. Zhang Y, Da RR, Guo HM, RenHilgenberg LG, Sobel RA, Tourtellotte WW, et al.
Axon reactive B cells clonally expanded in the cerebrospinal fluid of patients
with multiple sclerosis. J Clin Immunol (2005) 25:254–64. doi:10.1007/s10875-
005-4083-5
26. Schulze H, Schuler A, Stuber D, Dobeli H, Langen H, Huber G. Rat brain
glyceraldehyde-3-phosphate dehydrogenase interacts with the recombinant
cytoplasmic domain of Alzheimer’s ß-amyloid precursor protein. J Neurochem
(1993) 60:1915–22. doi:10.1111/j.1471-4159
27. Szalardya L, Zadoria D, Tanczosb E, Simuc M, Bencsika K, Vecseia dL, et al. Ele-
vated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple
sclerosis. Neurosci Lett (2013) 554:131–4. doi:10.1016/j.neulet.2013.08.069
28. Diab A, Deng C, Smith JD, Hussain RZ, Phanavanh B, Lovett-Racke AE, et al. Per-
oxisome proliferator-activated receptor-gamma agonist 15-deoxy-delta(12,14)-
prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J
Immunol (2002) 168:2508–15. doi:10.4049/jimmunol.168.5.2508
Frontiers in Neurology | Multiple Sclerosis and Neuroimmunology December 2014 | Volume 5 | Article 250 | 6
Mathur et al. Defective glucose metabolism in multiple sclerosis
29. Duvanel CB, Honegger P, Pershadsingh H, Feinstein D, Matthieu JM. Inhibi-
tion of glial cell proinflammatory activities by peroxisome proliferator activated
receptor gamma agonist confers partial protection during antimyelin oligoden-
drocyte glycoprotein demyelination in vitro. J Neurosci Res (2003) 71:246–55.
doi:10.1002/jnr.10471
30. Regenold WT, Phatak P, Makley MJ, Stone RD, Kling MA. Cerebrospinal fluid
evidence of increased extra-mitochondrial glucose metabolism implicates mito-
chondrial dysfunction in multiple sclerosis disease progression. J Neurol Sci
(2008) 275(1–2):106–12. doi:10.1016/j.jns.2008.07.032
31. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, et al. NADPH
oxidase expression in active MS lesions in relation to oxidative tissue damage
and mitochondrial injury. Brain (2012) 135:886–99. doi:10.1093/brain/aws012
32. Pandit A, Vadnal J, Houston S, Freeman E, McDonough J. Impaired regulation
of electron transport chain subunit genes by nuclear respiratory factor 2 in
multiple sclerosis. J. Neurol Sci (2009) 279:14–20. doi:10.1016/j.jns.2009.01.009
33. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondr-
ial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
Ann Neurol (2006) 59(3):478–89. doi:10.1002/ana.20736
34. Witte ME, Bø L, Rodenburg RJ, Belien JA, Musters R, Hazes T, et al. Enhanced
number and activity of mitochondria in multiple sclerosis lesions. J Pathol
(2009) 219(2):193–204. doi:10.1002/path.2582
35. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet
Neurol (2002) 1(4):232–41. doi:10.1016/S1474-4422(02)00102-3
36. Lu F, Selak M, O’Connor J, Croul S, Lorenzana C, Butunoi C, et al. Oxida-
tive damage to mitochondrial DNA and activity of mitochondrial enzymes in
chronic active lesions of multiple sclerosis. J Neurol Sci (2000) 177(2):95–103.
doi:10.1016/S0022-510X(00)00343-9
37. Mazzola JL, Sirover MA. Reduction of glyceraldehyde-3-phosphate dehydro-
genase activity in Alzheimer’s disease and in Huntington’s disease fibroblasts.
J Neurochem (2001) 76:442–9. doi:10.1046/j.1471-4159
38. Senatorov VV, Charles V, Reddy PH, Tagle DA, Chuang D. Overexpression and
nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a trans-
genic mouse model of Huntington’s disease. Mol Cell Neurosci (2003) 22:285–97.
doi:10.1016/S1044-7431(02)00013-1
39. Soucek T, Cumming R, Dargusch R, Maher P, Schubert D. The regulation
of glucose metabolism by HIF-1 mediates a neuroprotective response to
amyloid beta peptide. Neuron (2003) 39:43–56. doi:10.1016/S0896-6273(03)
00367-2
40. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW.
Incipient Alzheimer’s disease: microarray correlation analyses reveal major tran-
scriptional and tumor suppressor responses. Proc Natl Acad Sci U S A (2004)
101:2173–8. doi:10.1073/pnas.0308512100
41. Brooks WM, Lynch PJ, Ingle CC, Hatton A, Emson PC, Faull RL, et al. Gene
expression profiles of metabolic enzyme transcripts in Alzheimer’s disease. Brain
Res (2007) 1127:127–35. doi:10.1016/j.brainres.2006.09.106
42. Iñarrea P, Alarcia R, Alava MA, Capablo JL, Casanova A, Iñiguez C, et al. Mito-
chondrial complex enzyme activities and cytochrome c expression changes in
multiple sclerosis. Mol Neurobiol (2014) 49(1):1–9. doi:10.1007/s12035-013-
8481-z
43. Lin J, Diamanduros A, Chowdhury SA, Scelsa S, Latov N, Sadiq SA. Specific
electron transport chain abnormalities in amyotrophic lateral sclerosis. J Neurol
(2009) 256(5):774–82. doi:10.1007/s00415-009-5015-8
44. Chandrasekaran K, Giordano T, Brady DR, Stoll J, Martin LJ, Rapoport SI.
Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer
disease. Brain Res Mol Brain Res (1994) 24:336–40. doi:10.1016/0169-328X(94)
90147-3
45. Simonian NA, Hyman BT. Functional alterations in Alzheimer’s disease: selective
loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal
formation. J Neuropathol Exp Neurol (1994) 53:508–12. doi:10.1097/00005072-
199409000-00010
46. Safavizadeh N, Rahmani SA, Zaefizadeh M. Investigation of cytochrome c oxi-
dase gene subunits expression on the Multiple sclerosis. Indian J Hum Genet
(2013) 19(1):18–25. doi:10.4103/0971-6866.112879
47. Mahad D, Ziabreva I, Lassmann H, Turnbull D. Mitochondrial defects in acute
multiple sclerosis lesions. Brain (2008) 131:1722–35. doi:10.1093/brain/awn105
48. Broadwater L, Pandit A, Azzam S, Clements R, Vadnal J, Sulak M, et al. Analysis
of the mitochondrial proteome in multiple sclerosis cortex. Biochim Biophys
Acta (2011) 1812(5):630–41. doi:10.1016/j.bbadis.2011.01.012
49. Bae B, Hara MR, Cascio MB, Wellington CL, Hayden MR, Ross CA, et al. Mutant
Huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH. Proc
Natl Acad Sci U S A (2006) 103(9):3405–9. doi:10.1073/pnas.0511316103
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 26 May 2014; accepted: 13 November 2014; published online: 01 December
2014.
Citation: Mathur D, López-Rodas G, Casanova B and Marti MB (2014) Perturbed
glucose metabolism: insights into multiple sclerosis pathogenesis. Front. Neurol. 5:250.
doi: 10.3389/fneur.2014.00250
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the
journal Frontiers in Neurology.
Copyright © 2014 Mathur, López-Rodas, Casanova and Marti. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
www.frontiersin.org December 2014 | Volume 5 | Article 250 | 7
